Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in antiplatelet agents.

Jean-Michel Dogne1, Xavier de Leval, Patricia Benoit

  • 1Department of Medicinal Chemistry, University of Li ge, 1, av. de l H pital, B36 Sart-Tilman, Liege, 4000 Liege, Belgium. Jean-Michel.Dogne@ulg.ac.be

Current Medicinal Chemistry
|April 12, 2002
PubMed
Summary

Platelet aggregation is crucial in thromboembolic diseases. This review covers advances in antiplatelet agents like aspirin, ADP receptor antagonists, phosphodiesterase inhibitors, and glycoprotein IIb/IIIa inhibitors, focusing on chemical aspects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized Trials in Pregnancy.

JAMA·2026
Same author

Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications.

Journal of the Endocrine Society·2026
Same author

Techniques for measuring NETosis: A critical literature review and outlook for standardization.

Thrombosis research·2026
Same author

Why Pediatric CAR-T Therapies Still Lag Behind: Insights from Six Treatments Centrally Approved in Europe.

Clinical pharmacology and therapeutics·2026
Same author

Commentary: 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea.

Frontiers in public health·2026
Same author

Device-Induced Thrombosis in Blood-Contacting Medical Devices: Mechanisms and Emerging Prevention Strategies.

Advanced healthcare materials·2026

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Hematology

Background:

  • Platelet aggregation is central to thromboembolic diseases (e.g., myocardial infarction, stroke).
  • Aspirin has been the standard antiplatelet therapy, but new agents have emerged.
  • Understanding antiplatelet therapy is vital for managing thrombosis complications.

Purpose of the Study:

  • To review recent advancements in antiplatelet agents.
  • To highlight the chemical aspects of these drugs.
  • To discuss the evolving landscape of antiplatelet therapy.

Main Methods:

  • Literature review of antiplatelet agents.
  • Focus on chemical properties and development.
  • Analysis of aspirin, phosphodiesterase inhibitors, ADP receptor antagonists, and GP IIb/IIIa inhibitors.

Related Experiment Videos

Main Results:

  • Significant expansion in the antiplatelet drug arsenal beyond aspirin.
  • Development of ADP receptor antagonists (e.g., clopidogrel) and phosphodiesterase inhibitors (e.g., dipyridamole).
  • Emergence of Glycoprotein (GP) IIb/IIIa inhibitors, with new generations showing promise.

Conclusions:

  • The antiplatelet armamentarium has grown substantially.
  • Newer agents, particularly GP IIb/IIIa inhibitors, offer expanded therapeutic potential.
  • Chemical insights are key to understanding and developing these vital medications.